Art. -Nr.: HY-124806

TTP-8307

Name: TTP-8307
Brand: MedChemExpress
SKU: HY-124806
Price: 320.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC₅₀=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 950225-08-8
Formel: C₂₇H₂₁FN₄O
Molecular Weight:436.48

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

TTP-8307 Chemical Structure

CAS. Nr.: 950225-08-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Vero	CC₅₀	>50 μM Compound: TTP-8307	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	[PMID: 20576576]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>50 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	>60 μM Compound: TTP-8307	Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.091 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.27 μM Compound: TTP-8307	Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.51 μM Compound: TTP-8307	Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.58 μM Compound: TTP-8307	Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.65 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.77 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.8 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.85 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.99 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	1.2 μM Compound: TTP-8307	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	1.22 μM Compound: TTP-8307	Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	1.9 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	15.3 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	17.7 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	19.8 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	5.34 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	6 μM Compound: TTP-8307	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]

In Vitro

TTP-8307 targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC₅₀ of 1.2 μM. TTP-8307 inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC₅₀ of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307^[1].
TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 950225-08-8
Appearance Solid
Molecular Weight 436.48
Formel C₂₇H₂₁FN₄O
Color White to light yellow
SMILES

O=C(N[C@@H](C1=CC=C(F)C=C1)C)C2=CC=CC(C3=CN=C(C4=CC5=C(C=N4)C=CC=C5)N3)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Proc Natl Acad Sci U S A

Oxysterol binding protein regulates the resolution of TLR-induced cytokine production in macrophages. [Abstract]

2024 Aug 13;121(33):e2406492121. PMID: 39361877
J Med Virol

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]

2025 Oct;97(10):e70655. PMID: 41117261

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (229.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2911 mL

11.4553 mL

22.9106 mL

5 mM

0.4582 mL

2.2911 mL

4.5821 mL

10 mM

0.2291 mL

1.1455 mL

2.2911 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.73 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.73 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53(5):1850-7. [Content Brief]

[2]. Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2911 mL	11.4553 mL	22.9106 mL	57.2764 mL
	5 mM	0.4582 mL	2.2911 mL	4.5821 mL	11.4553 mL
	10 mM	0.2291 mL	1.1455 mL	2.2911 mL	5.7276 mL
	15 mM	0.1527 mL	0.7637 mL	1.5274 mL	3.8184 mL
	20 mM	0.1146 mL	0.5728 mL	1.1455 mL	2.8638 mL
	25 mM	0.0916 mL	0.4582 mL	0.9164 mL	2.2911 mL
	30 mM	0.0764 mL	0.3818 mL	0.7637 mL	1.9092 mL
	40 mM	0.0573 mL	0.2864 mL	0.5728 mL	1.4319 mL
	50 mM	0.0458 mL	0.2291 mL	0.4582 mL	1.1455 mL
	60 mM	0.0382 mL	0.1909 mL	0.3818 mL	0.9546 mL
	80 mM	0.0286 mL	0.1432 mL	0.2864 mL	0.7160 mL
	100 mM	0.0229 mL	0.1146 mL	0.2291 mL	0.5728 mL

Bioz

Keywords

TTP-8307

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

TTP-8307

Ribavirin

Ledipasvir

Sofosbuvir

Glecaprevir

Ribavirin (Standard)

NHC-diphosphate

Sofosbuvir (Standard)

Simeprevir

NHC-triphosphate

Velpatasvir

Samatasvir

Dasabuvir

Publications Citing Use of MedChemExpress (MCE) TTP-8307

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

TTP-8307

Ribavirin

Ledipasvir

Sofosbuvir

Glecaprevir

Ribavirin (Standard)

NHC-diphosphate

Sofosbuvir (Standard)

Simeprevir

NHC-triphosphate

Velpatasvir

Samatasvir

Dasabuvir

Publications Citing Use of MedChemExpress (MCE) TTP-8307

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

TTP-8307 Related Classifications

HY-124806 Related Classifications

Bioz